Alpha-Pinene

Alpha-Pinene – PatientsCann UK Skip to main content Back to Terpenes Guide Alpha-Pinene α-Pinene pronounced: AL-fuh PY-neen Smells like a pine forest. Found in pine needles and rosemary. Monoterpene Boiling point: 156°C Terpene type Monoterpene Boiling point 156°C Primary aroma Pine Key effect Focus Aroma profile How it Smells The aroma of alpha-pinene is described as: PineResinousSharp WoodFresh Forest Found naturally in: Pine needles, rosemary, basil, dill, eucalyptus Effects Linked Effects FocusEnergyAnti-inflammatoryMemory support These effects are based on early-stage research in animals and cells. They are not proven in humans. Do not change your treatment based on this information. About What is Alpha-Pinene? Alpha-pinene is the most abundant terpene in the natural world. If you have ever walked through a pine forest and taken a deep breath, you have experienced it directly. It gives pine trees their sharp, clean, resinous smell and is the dominant scent in rosemary and eucalyptus. In cannabis, alpha-pinene is one of the secondary terpenes found in many strains. It contributes a piney, fresh edge to the overall aroma. Strains high in pinene are sometimes described as smelling like a forest floor or fresh herbs (Booth and Bohlmann, 2019). Effects in detail What the Research Says Alpha-pinene is one of the most studied terpenes for its effects on the mind. It is a known bronchodilator at low concentrations, meaning it can help open up the airways. Weston-Green et al. (2021) reviewed evidence suggesting pinene may support memory and alertness by blocking enzymes that break down acetylcholine, a brain chemical involved in memory and attention. This is particularly interesting in the context of medical cannabis, because some people report that high-THC products can affect memory temporarily. The presence of alpha-pinene in a strain may partially counteract this effect (Russo, 2011). It also has well-documented anti-inflammatory properties. Everyday sources Where You Find it in Daily Life Rosemary is probably the easiest everyday source of alpha-pinene. When you rub a sprig of rosemary between your fingers, the sharp, piney smell you get is largely alpha-pinene. Basil, dill, and parsley also contain it, as do many coniferous trees. Pine-scented cleaning products and air fresheners almost always use pinene as the fragrance source. It is considered safe at normal exposure levels and is approved as a food flavouring in many countries. Research Key Studies Weston-Green et al. (2021) published a detailed review of the potential of pinene as a medicine for brain health. They found evidence from preclinical studies that it can reduce anxiety, improve memory, and act as a neuroprotective compound, though human clinical trials are still limited. Russo (2011) highlighted alpha-pinene specifically as a terpene that may modulate the psychoactive effects of THC by inhibiting acetylcholinesterase, helping to maintain working memory. Nuutinen (2018) confirmed these findings across a broader review of cannabis terpene pharmacology. Previous Limonene Next Beta-Caryophyllene Back to full Terpenes Guide Important: The information on this page is for education only. It is not medical advice. Terpene research is still in its early stages. Many studies have been done in animals, not yet in people. Always speak to your doctor before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Booth, J.K. and Bohlmann, J. (2019) ‘Terpenes in Cannabis sativa: from plant genome to humans’, Plant Science, 284, pp. 67-72. doi: 10.1016/j.plantsci.2019.03.022. Nuutinen, T. (2018) ‘Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus’, European Journal of Medicinal Chemistry, 157, pp. 198-228. doi: 10.1016/j.ejmech.2018.07.076. Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. Weston-Green, K. et al. (2021) ‘A review of the potential use of pinene and linalool as terpene-based medicines for brain health’, Frontiers in Psychiatry, 12, 583211. doi: 10.3389/fpsyt.2021.583211.

Limonene

Limonene – PatientsCann UK Skip to main content Back to Terpenes Guide Limonene D-Limonene pronounced: LIM-oh-neen The bright, citrus terpene. Found in lemon peel and orange rind. Monoterpene Boiling point: 177°C Terpene type Monoterpene Boiling point 177°C Primary aroma Citrus Key effect Uplifting Aroma profile How it Smells The aroma of limonene is described as: CitrusTangyLemonOrangeZesty Sour Found naturally in: Lemon and orange peel, peppermint, rosemary, juniper Effects Linked Effects UpliftingCalmStress reliefFocus These effects are based on early-stage research in animals and cells. They are not proven in humans. Do not change your treatment based on this information. About What is Limonene? Limonene is the terpene responsible for that sharp, clean citrus smell. It is one of the most widely found terpenes in nature and is the main compound that gives lemon and orange peel their unmistakable scent. In cannabis, strains high in limonene often smell like a fresh citrus fruit or lemon sherbet. As a monoterpene, limonene is a relatively simple molecule that is highly volatile, meaning it evaporates quickly. This is why cutting a lemon releases that burst of smell almost immediately. In cannabis, limonene is often most noticeable in the first wave of aroma when a jar is opened (Booth and Bohlmann, 2019). Effects in detail What the Research Says Limonene is strongly associated with mood-lifting and stress-reducing effects. Laboratory studies have found it can reduce anxiety-like behaviour in animals (Nuutinen, 2018). Several clinical and preclinical studies suggest it may act on serotonin and dopamine pathways in the brain, which are linked to mood regulation. Research by Baram et al. (2022) found that limonene, like myrcene, can activate CB2 receptors. This means it is not merely adding aroma: it may interact with the body’s endocannabinoid system directly. Some studies also report anti-inflammatory and antioxidant properties at higher concentrations. Everyday sources Where You Find it in Daily Life Limonene is everywhere in the kitchen. The white pith and coloured skin of any citrus fruit contain high concentrations of it. Lemon-flavoured cleaning products almost always use limonene as the active fragrance ingredient, and it is approved as a food flavouring across the UK and EU. You will also find limonene in rosemary, juniper berries, and peppermint. It is used extensively in the fragrance industry and is one of the most commonly added flavours in food and drinks. Research Key Studies A key study by Russo (2011) highlighted limonene as a terpene with notable anti-anxiety and antidepressant potential based on animal and in vitro research. He proposed that the entourage effect partly relies on limonene interacting with serotonin receptors. Baram et al. (2022) later confirmed that limonene can activate endocannabinoid receptors at physiologically relevant concentrations. This was a significant finding because it moved limonene from a simple aromatic compound to a potentially pharmacologically active molecule in its own right. Previous Myrcene Next Alpha-Pinene Back to full Terpenes Guide Important: The information on this page is for education only. It is not medical advice. Terpene research is still in its early stages. Many studies have been done in animals, not yet in people. Always speak to your doctor before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Baram, L. et al. (2022) ‘Major cannabis terpenes, applied individually and in combination, activate endogenous cannabinoid CB1 and CB2 receptors’, Frontiers in Pharmacology, 13, 1040962. doi: 10.3389/fphar.2022.1040962. Booth, J.K. and Bohlmann, J. (2019) ‘Terpenes in Cannabis sativa: from plant genome to humans’, Plant Science, 284, pp. 67-72. doi: 10.1016/j.plantsci.2019.03.022. Nuutinen, T. (2018) ‘Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus’, European Journal of Medicinal Chemistry, 157, pp. 198-228. doi: 10.1016/j.ejmech.2018.07.076. Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x.

Myrcene

Myrcene – PatientsCann UK Skip to main content Back to Terpenes Guide Myrcene Beta-Myrcene pronounced: MUR-seen The most common terpene in cannabis. Found in mangoes and hops. Monoterpene Boiling point: 167°C Terpene type Monoterpene Boiling point 167°C Primary aroma Earthy Key effect Relaxing Aroma profile How it Smells The aroma of myrcene is described as: EarthyMuskyClovesCardamomSweet Found naturally in: Mangoes, hops, lemongrass, thyme, bay leaves Effects Linked Effects RelaxingSleep supportPain reliefAnti-inflammatory These effects are based on early-stage research in animals and cells. They are not proven in humans. Do not change your treatment based on this information. About What is Myrcene? Myrcene is the terpene found in the highest amounts in most cannabis strains. It is why so many varieties have that earthy, slightly musky smell with a hint of ripe fruit. You are already familiar with it even if you did not know the name: that rich smell when you bite into a ripe mango, or the hoppy scent of beer, both come from myrcene. Chemically, myrcene is a small monoterpene molecule (Booth and Bohlmann, 2019). It evaporates quickly at room temperature, which is why the smell hits you straight away when you open a sealed container. Effects in detail What the Research Says Early research suggests myrcene may have sedative and muscle-relaxant properties (Nuutinen, 2018). Studies in animals have found it can reduce pain signals and lower inflammation (Baram et al., 2022). People who use cannabis strains high in myrcene often describe feeling deeply relaxed and sleepy. Myrcene is also thought to play a role in the entourage effect. Some researchers believe it may help other compounds, including THC and CBD, cross into the brain more easily, which could make effects feel stronger or come on faster (Russo, 2011). Everyday sources Where You Find it in Daily Life You can find myrcene in many everyday foods. Mangoes are the richest natural source. Hops (used to brew beer) are packed with it, and it is what gives India Pale Ale its distinctive earthy and slightly sweet bitterness. Bay leaves, lemongrass, and thyme also contain myrcene in smaller amounts. Some people eat a ripe mango about 45 minutes before using medical cannabis. The idea is that the myrcene in the mango might add to the overall effect. There is no strong clinical evidence for this yet, but it is a harmless experiment if your doctor approves. Research Key Studies A 2022 study by Baram et al. found that myrcene activates both CB1 and CB2 receptors in the body. These are the same receptors that THC and CBD work on. This supports the idea that terpenes are more than just smell molecules. Russo (2011) reviewed the science behind the entourage effect and identified myrcene as one of the most important terpenes for cannabis pharmacology. A later study by LaVigne et al. (2021) confirmed that cannabis terpenes, including myrcene, can enhance the activity of cannabinoids at low concentrations. Previous Camphene Next Limonene Back to full Terpenes Guide Important: The information on this page is for education only. It is not medical advice. Terpene research is still in its early stages. Many studies have been done in animals, not yet in people. Always speak to your doctor before changing your treatment. PatientsCann UK does not recommend any specific cannabis product. References Baram, L. et al. (2022) ‘Major cannabis terpenes, applied individually and in combination, activate endogenous cannabinoid CB1 and CB2 receptors’, Frontiers in Pharmacology, 13, 1040962. doi: 10.3389/fphar.2022.1040962. Booth, J.K. and Bohlmann, J. (2019) ‘Terpenes in Cannabis sativa: from plant genome to humans’, Plant Science, 284, pp. 67-72. doi: 10.1016/j.plantsci.2019.03.022. LaVigne, J.E. et al. (2021) ‘Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity’, Scientific Reports, 11(1), 8232. doi: 10.1038/s41598-021-87740-8. Nuutinen, T. (2018) ‘Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus’, European Journal of Medicinal Chemistry, 157, pp. 198-228. doi: 10.1016/j.ejmech.2018.07.076. Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x.

Terpenes

Terpenes – PatientsCann UK Skip to terpene library PatientsCann UK  ·  Education Understanding Terpenes Terpenes are the natural scents and flavours in cannabis. They shape how each strain smells, tastes, and feels. This guide uses trusted science, an interactive wheel, and real KAST fingerprint data from actual cannabis batches. Real KAST data What are terpenes? Terpenes are natural chemicals made by plants, including cannabis. They give plants their smell and flavour. When you open a cannabis medicine and notice an earthy, citrus, or pine smell, that is terpenes at work. Cannabis makes over 200 different terpenes (Booth and Bohlmann, 2019). Each strain has its own mix. That is why some strains smell like lemons, some like berries, and some like a damp forest. You find the same terpenes in everyday food: Myrcene is in mangoes, Limonene is in lemon peel, Linalool is in lavender. Terpenes may also change how cannabis affects the body by working alongside cannabinoids like THC and CBD. Scientists call this the “entourage effect” (Russo, 2011). The Entourage Effect Think of a band. THC and CBD are the lead singers. Terpenes are the rest of the band. On their own each part is useful, but together they can make something richer and more powerful. Dr Ethan Russo found evidence that terpenes can help cannabis work better for things like pain, anxiety, and sleep (Russo, 2011). Israeli researchers then showed that 16 cannabis terpenes can activate the same receptors in the body that cannabinoids use (Baram et al., 2022). This page shares what scientists have found so far. It is not medical advice. Always speak to your doctor before changing your treatment. Interactive Terpene Wheel Click or tap any slice to learn about that terpene. Use arrow keys to navigate by keyboard. Adapted from the Cicada Terpene Wheel (Cicada Jersey, 2020). Tap a slice or use the list below • Arrow keys navigate Not using a mouse? Use the numbered list below. Each button loads full details. Click any slice to learn about that terpene. Adapted from Cicada Terpene Wheel (Cicada Jersey, 2020) KAST — Aromatic Sensory Translation Real Terpene Fingerprints KAST turns complex terpene lab results into a visual fingerprint anyone can read. Each leaf-shaped band is one compound. A wider leaf means more of that compound in the batch. Live batch data  ·  KA Pharmaceuticals SA Six real CSC Cannacosta batches The fingerprints below use real NIR spectroscopy data measured in May 2026. Hover over any leaf on the fingerprint or click a compound name to highlight it. Switch batches using the arrows or thumbnails. Zone I Oxidised & Floral Caryophyllene oxide, bisabolol, linalool Zone II Light Terpenes Eudesmol, limonene, pinene Zone III Mid Sesquiterpenes Caryophyllene, elemene, bisabolene Zone IV Heavy & Dominant Aromadendrene, guaiol, phytol, myrcene CSC Cannacosta · Grape Runtz Batch 1 of 6 Zone I Zone II Zone III Zone IV KAST Terpene Fingerprint Band width = concentration Compounds Aromatic Load 65.42 THC Total 18.81% Dominant Myrcene Moisture 6.43% How to read a KAST fingerprint Each leaf = one compound. The wider the leaf, the more of that compound is in the batch. Very thin or invisible leaves mean only trace amounts. Read top to bottom. The fingerprint has four zones. Zone I at the top holds oxidised and floral terpenes. Zone IV at the base holds heavy sesquiterpenes and diterpenes including Myrcene. Compare batches. Load a different batch using the arrows or thumbnails. Differences in leaf width at the same position show how the mix has changed between harvests. Source: KA Pharmaceuticals SA (2026) How to Read a KAST Profile. Field Guide, Protocol v1.0. Source: KA Pharmaceuticals SA (2026) KAST Profile Records: CSC Cannacosta batch series, KAST-26-953LSKE3. Real NIR spectroscopy data measured May 2026. The KAST profile is for comparison and information only. It is not medical advice. Full library Explore Each Terpene Select any card to open the full page for that terpene. Use the filter buttons to narrow by effect. Filter: All Relaxing Uplifting Focus Sleep Pain relief Anti-inflammatory Calm Sources: Terpene wheel adapted from Cicada Jersey (2020). KAST glyph and batch data from KA Pharmaceuticals SA (2026). Terpene data from Cannabis Terpenes Reference Database v2.0.0, Cannigma (Weil, 2022), Booth and Bohlmann (2019), and Russo (2011). References Abstrax Tech (2023) Linalool and beta-myrcene anxiolytic study with Western Washington University. Available at: https://abstraxtech.com/pages/terpene-research (Accessed: 29 May 2026). Baram, L. et al. (2022) ‘Major cannabis terpenes, applied individually and in combination, activate endogenous cannabinoid CB1 and CB2 receptors’, Frontiers in Pharmacology, 13, 1040962. doi: 10.3389/fphar.2022.1040962. Booth, J.K. and Bohlmann, J. (2019) ‘Terpenes in Cannabis sativa: from plant genome to humans’, Plant Science, 284, pp. 67-72. doi: 10.1016/j.plantsci.2019.03.022. Cannabis Terpenes Reference Database (2025) Cannabis Terpenes Comprehensive Database, Version 2.0.0. 200 records. Structural classifications: Hemiterpenes, Monoterpenes, Sesquiterpenes, Diterpenes. Cicada Jersey (2020) Terpene Wheel. Available at: https://cicada.je/terpene-wheel/ (Accessed: 29 May 2026). Francomano, F. et al. (2025) ‘The entourage effect in cannabis medicinal products: a comprehensive review’, Pharmaceuticals, 18(3), 378. doi: 10.3390/ph18030378. Hashiesh, H.S. et al. (2021) ‘A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene’, Biomedicine and Pharmacotherapy, 140, 111639. doi: 10.1016/j.biopha.2021.111639. KA Pharmaceuticals SA (2026) KAST Profile Records: CSC Cannacosta batch series, KAST-26-953LSKE3. Protocol v1.0. Issued May 2026. LaVigne, J.E. et al. (2021) ‘Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity’, Scientific Reports, 11(1), 8232. doi: 10.1038/s41598-021-87740-8. Nuutinen, T. (2018) ‘Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus’, European Journal of Medicinal Chemistry, 157, pp. 198-228. doi: 10.1016/j.ejmech.2018.07.076. Russo, E.B. (2011) ‘Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects’, British Journal of Pharmacology, 163(7), pp. 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x. Weil, M. (2022) ‘Most common cannabis terpenes and what they do’, Cannigma. Available at: https://cannigma.com/plant/a-brief-history-of-terpenes/ (Accessed: 29 May 2026). Weston-Green, K. et al. (2021) ‘A review of the potential use of pinene and linalool as terpene-based medicines for brain health’, Frontiers in Psychiatry, 12, 583211. doi: 10.3389/fpsyt.2021.583211. Important: The information on this page is for education only. It is not medical advice. Terpene research is

UK-First Inpatient Medical Cannabis Policy

Devon Partnership NHS Trust has formally approved CD21, a Standard Operating Procedure that gives medical cannabis patients a clear, safe pathway to continue their lawful prescriptions while admitted to hospital. Here is what it means for you.

Bedrocan May 2026 Press Release

New Bedrocan® Concentrate Opens Up More Ways to Take Your Prescription – PatientsCann UK Skip to main content Industry News · Prescribing Options A trusted flower,now in a new form Bedrocan® — the world’s most prescribed pharmaceutical cannabis flower — is set to become available as a standardised extract concentrate for the first time. For patients, that could mean the same trusted medicine available in more ways than ever before. PatientsCann UK · Industry News · 19 May 2026 Jump to: What Is It? Formulations Why It Matters Timeline 20+ years of Bedrocan® pharmaceutical cannabis production trusted by doctors worldwide 70% THC concentration in the new Becanex PIEX Bedrocan® extract — preserving the full cannabinoid and terpene fingerprint 5+ preparation formats now possible from a single standardised concentrate, from capsules to inhalation 2026 Target launch date for pharmacy ordering across Europe, with Germany as the first market What Is It? The Bedrocan® flower you know — in concentrated form If you have been prescribed Bedrocan® flower, you will know it as one of the most consistent and well-studied pharmaceutical cannabis products available. Grown in EU-GMP-certified facilities in the Netherlands and Denmark by Bedrocan International, it has been the benchmark for standardised medical cannabis for more than two decades. Now, that same product is set to take a new form. Berlin-based extraction specialist Becanex GmbH has developed the Becanex PIEX Bedrocan® 70% THC Concentrate — an extract that, for the first time, brings the full cannabinoid and terpene fingerprint of the Bedrocan® flower into a standardised, pharmacist-ready concentrate. The extract is produced using Becanex’s proprietary PIEX (Plant-Identical Extraction) process, which is specifically designed to preserve what makes a particular cannabis strain therapeutically distinctive. In simpler terms: this is not a generic cannabis extract. It is Bedrocan® in a bottle — the same profile, in a versatile new format. What makes it different from other extracts? Many cannabis extracts are produced to isolate one or two cannabinoids — often just THC or CBD — and discard the rest. The PIEX method takes a different approach, retaining the full spectrum of naturally occurring cannabinoids and terpenes in proportions that match the original flower. Becanex describes this as “a fingerprint” of the source material, and that precision matters clinically: the interaction between cannabinoids and terpenes — sometimes called the entourage effect — is increasingly recognised as relevant to therapeutic outcomes. The result is a concentrate that is both highly potent (at 70% THC) and pharmacologically familiar to doctors and pharmacists who have already been prescribing Bedrocan® flower. “We have always been precise about how we grow our cannabis. Becanex is equally precise about how they extract it. That shared attention to detail is what makes this product worth putting in front of pharmacists, prescribers and patients. The concentrate now enables doctors to prescribe our main product Bedrocan® in multiple compounding formulations.” Jaap Erkelens — CEO, Bedrocan International Formulations More ways for pharmacists to prepare your medicine One of the most significant implications of this product for patients is flexibility. A standardised concentrate that sits in a pharmacy’s dispensary can be compounded into a wide range of preparation formats, tailored to what works best for each individual. The Becanex PIEX Bedrocan® concentrate is specifically designed for the following preparations: Oral solution Capsules Suppositories Topical forms Inhalation dosage Vaporisation What this means in practice for patients For patients currently prescribed Bedrocan® flower, this is particularly significant. If inhalation becomes difficult — whether due to respiratory concerns, lifestyle factors, or simply personal preference — a concentrated extract from the same strain could potentially be offered as an oral or capsule-based alternative, without switching to an entirely different product. The vaporisation option is also noteworthy: the concentrate can be vaporised directly, giving patients an additional inhalation route alongside the flower. This kind of flexibility within a single, consistent product profile is exactly the kind of development that helps both patients and prescribers make evidence-informed adjustments over time. It is important to note that any change to your prescription formulation must always be discussed with and authorised by your prescribing specialist. The availability of a new format does not mean your prescription changes automatically — it expands the options your clinician can consider for you. “Patients who have found a cannabis strain that works well for them shouldn’t have to compromise if they need it in a different form. With Bedrocan as our partner, we can now offer prescribers exactly that — building on a strain they already know and trust.” Sebastian Kamphorst — Director, Becanex GmbH Why It Matters Why standardisation matters for patients Consistency you can rely on One of the greatest frustrations for patients on prescribed cannabis is variability. A standardised extract — manufactured under GMP conditions from a named, controlled cultivar — reduces that uncertainty. You and your prescriber know what to expect. No need to start from scratch For patients and doctors who have already found that Bedrocan® works, this product preserves that relationship. Switching formulation format does not mean re-establishing which strain or cannabinoid profile is therapeutically appropriate. Pharmacist flexibility Compounding pharmacies are central to how many patients receive their prescribed cannabis. A concentrate designed specifically for compounding gives pharmacists more tools to prepare bespoke preparations that suit individual clinical needs. Germany first, Europe next Germany is the first market for the launch, which reflects its position as the most developed regulated medical cannabis market in Europe. UK patients should watch this development closely — it signals the direction of travel for product diversity across Europe. A decade in the making This collaboration is not simply a commercial arrangement — it has roots going back more than ten years. As early as 2014, the founding team behind Becanex worked with Bedrocan under a scientific licence to develop the first extracts from the Bedrocan® flower. At the time, the regulatory framework to bring such a product to market did not exist. Today, it does. Kamphorst reflects on this directly: the team is not

Landmark Ruling for Safety-Critical Role

A professional, clinical graphic featuring a silhouette of a person in a safety hard hat. Bold text reads "Safety-Critical Role Case Law," highlighting the landmark May 2026 ruling that shifted UK employment views on medical cannabis.

A medical cannabis patient who was banned from the rail industry for five years after testing positive for THC from his prescribed medication has won a significant victory at the Employment Appeal Tribunal. This ruling changes the legal landscape for every prescribed cannabis patient in safety-critical employment in the UK.

Prescription Direction in Medical Cannabis: Guidance for Clinicians and Patients

Prescription Direction in Medical Cannabis: Guidance for Clinicians and Patients – PatientsCann UK Skip to main content Education GMC Guidance Aligned CQC Standards Prescription Direction in Medical Cannabis:Guidance for Clinicians and Patients In the UK, most medical cannabis, legally termed cannabis-based medicinal products (CBPMs), is prescribed by specialists in the private sector. Issues around prescription direction, where patients are steered toward specific pharmacies or restricted product lists, have become critical ethical and professional considerations for the sector. PatientsCann UK · Education & Guidance · Published 23 March 2026 · ~6 min read GMC General Medical Council | Prescribing Standards Aligned with GMC guidance on cannabis-based products for medicinal use (2026) CQC Care Quality Commission Provider expectations for independent CBPM clinics Reviewed February 2026 Jump to Definition Legal Framework For Clinicians For Patients Summary References At a Glance Three principles that underpin this guidance Patient Owns the Prescription Once issued, a valid prescription belongs to the patient — not the clinic. Patients may take it to any appropriately registered pharmacy. Clinical Grounds Only Any direction toward a specific pharmacy or product must be clinically justified. Commercial or operational preferences are not sufficient grounds. Regulatory Accountability Independent CBPM clinics are regulated by the CQC. Professional conduct is subject to GMC oversight. Patients can raise concerns with either body. Definition What is “Prescription Direction”? Key Term ‘Prescription Direction’ refers to any practice in which a healthcare provider influences or obligates a patient to use a particular pharmacy or dispensing service, or restricts which products may be prescribed based on a clinic’s internal formulary rather than clinical considerations alone. For standard prescription-only medicines, and CBPMs alike, once a valid prescription is issued, the patient, not the issuing clinic or prescriber, owns the prescription and has the right to have it dispensed at any appropriate pharmacy. Professional guidance makes no provision for locking prescriptions to a particular dispensing outlet on non-clinical grounds. [1] This issue has grown in practical significance as the UK’s private medical cannabis sector has expanded. Patients, many managing chronic and complex conditions, must be able to access the most suitable products at pharmacies they can practically use and afford. Legal & Regulatory Framework Prescribing medical cannabis in the UK Who Can Prescribe GMC Specialist Register Only CBPMs (excluding those with a marketing authorisation like Sativex®) are predominantly unlicensed medicines. The law restricts their prescription to doctors on the GMC’s Specialist Register, acting within their area of competence. [3] Clinic Regulation Care Quality Commission Independent clinics prescribing CBPMs are regulated by the CQC, which requires clinical governance, prescriber competence, patient safety, informed consent, and compliance with controlled drugs legislation. [4] Pharmacy Supply Any Registered Pharmacy There is no single official UK “list” of pharmacies for CBPMs. Any pharmacy that is properly registered and complies with regulatory standards may dispense them once presented with a valid prescription. [5] Unlicensed Medicines and Clinical Responsibility Unlicensed medicines entail additional responsibilities for prescribers because they have not undergone the full range of regulatory assessments for safety, quality and efficacy. Prescribers must therefore be confident that the product is appropriate for the individual patient, and must explain to patients the unlicensed nature of the treatment as part of informed decision-making. [1][5] Shared Care Arrangements NHS England guidance confirms that while subsequent prescriptions may sometimes be made under shared care arrangements, initial prescriptions must be authorised by a specialist clinician. This reinforces the importance of maintaining robust clinical oversight throughout a patient’s CBPM treatment pathway. [2] Conflicts of Interest The CQC guidance confirms that providers must ensure prescribing decisions are clinically justified, appropriately documented, and made in the best interests of the patient, with systems in place to manage risk and avoid conflicts of interest. This includes ensuring that organisational or commercial arrangements do not compromise professional judgement or patient choice in prescribing or supply pathways. [4] For Clinicians Responsibilities for prescribing doctors Many private medical cannabis clinics operate internal formularies, lists of products they commonly prescribe based on clinician familiarity, supply arrangements, or existing protocols. There may be legitimate clinical reasons to prefer certain products (e.g. formulations with established pharmacological profiles or evidence bases). However, clinicians must never refuse to consider other products solely because they are not on an internal clinic list, without clinical reasoning. [1] Clinical judgement during prescribing must always focus on the patient’s individual needs rather than operational convenience or commercial preference. This is consistent with all prescribing guidance for individualised care. Do’s for Clinicians Respect patient choice of pharmacy — inform patients they may take their prescription to any appropriately registered pharmacy capable of dispensing CBPMs Provide balanced product information — discuss evidence, risks, benefits, and availability of relevant CBPMs to enable informed decision-making Explain formulary limits transparently — if prescribing experience is concentrated on certain products, clarify this and discuss why other products may be clinically appropriate Follow GMC prescribing standards — ensure decisions are based on clinical evidence and patient needs, not commercial relationships [1] Operate within CQC governance expectations — maintain transparency in prescribing practices and avoid commercial influence on clinical decision-making [4] Don’ts for Clinicians Do not require patients to use a particular pharmacy for non-clinical reasons Do not imply that prescriptions are “owned” by the clinic or that patients must dispense through a preferred partner Do not limit prescribing to products on an internal formulary if other products are clinically suitable and available Do not allow commercial arrangements with pharmacies or manufacturers to influence clinical prescribing choices Any practice that restricts patient choice on non-clinical grounds may undermine professional ethics and patient trust. For Patients Your rights as a CBPM patient Know Your Rights What you are entitled to You have the right to choose the pharmacy that dispenses your prescription, provided it is registered and authorised to supply controlled drugs and CBPMs [5] A prescription is your legal document, it may be taken to any suitable registered pharmacy Clinicians must explain the clinical basis for any recommended product, including risks and benefits, to support informed

PatientsCann UK Statement on NPCC Guidance for Policing Medical Cannabis Patients

PatientsCann UK: NPCC Policing Statement Statement Policing January 2026 PatientsCann UK Statement on NPCC Guidance for Policing Medical Cannabis Patients The NPCC has instructed forces to treat medicinal cannabis patients as “patients first, suspects second.” We welcome this, with important caveats about the gap between guidance and street-level reality. PatientsCann UK·Official Statement·7 January 2026 What the NPCC Guidance Says Officers should treat those in lawful possession as patients first, suspects second People with a valid prescription should be assumed to be patients until proven otherwise A Cancard is not legally required and its absence cannot be used against a patient Our Concerns Significant proportion of officers may still be unaware medical cannabis is legally prescribable Some forces lack internal training or up-to-date briefing materials Guidance on paper does not automatically become consistent street-level practice Why Guidance Is Not Enough Without Understanding It is an ongoing reality that many frontline officers still lack accurate awareness of the legal status of medical cannabis. Independent research has indicated that a significant proportion of officers may still be unaware that medical cannabis can be legally prescribed in the UK, even years after the law changed in 2018. Previous Freedom of Information responses showed that some police forces did not have internal training or up-to-date briefing materials on this subject, leaving officers to rely primarily on older Home Office circulars and personal discretion. This gap between policy and practice raises serious concerns. Unless officers are consistently aware of the legal framework, understand how to verify lawful possession, and are trained to apply the guidance, the lived experience of patients may not improve significantly. On Cancard: The Clarification That Was Needed The NPCC guidance confirms that a Cancard is not legally required for patients with a valid prescription, a vital clarification given the confusion that has surrounded this scheme. Cancard was originally introduced to assist officers in identifying individuals claiming medical need. However, it has always been a discretionary tool, not legal proof of lawful possession. Simply put: A card indicating intent or condition does not change the law. What matters is the prescription. Patients with a valid prescription from an appropriate specialist clinician are in lawful possession, with or without a card. PatientsCann UK’s Position We welcome this guidance as a meaningful step forward, but we call on the NPCC, individual forces, and the College of Policing to follow through with mandatory training, updated force policies, and a clear escalation route for patients who experience non-compliant policing. Guidance without enforcement infrastructure will not protect patients on the ground. PatientsCann UKUK’s Medical Cannabis Patient Organisation · patientscann.co.uk